Pharmacyte Biotech Inc (OTCMKTS:PMCB) Issued Certificates Of Analysis On Cells Used For Pancreatic Cancer Therapy By Eurofins


Pharmacyte Biotech Inc (OTCMKTS:PMCB) has been issued with a certificate for Analysis and final reports for all the analysis and tests that were done by Eurofins, its contractor. The analysis was done on cells obtained from PharmaCyte’s Master Cell Bank (MCB). PharmaCyte Biotech is a clinical stage company that is engaged in the development of cellular cancer and diabetes therapies using Cell-in-a-Box®, the company’s signature live-cell encapsulation technology.

The cells which underwent the testing will be encapsulated and later used in a clinical trial that PharmaCyte will be undertaking in patients that suffer from locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).

Application for IND

In a statement, Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte said that they are happy that they finally got the final report from the intense testing of the MCB cells from Eurofins. He added that Eurofins has issued Certificates of Analysis for all the 29 tests that were done. Waggoner said that the reports that were generated from each of the tests will help the company in its IND submission to the FDA. This is because the FDA required the company to carry out all the tests that were done on the cells.

First clinical trial

In other news, the company has announced that it will be undertaking its first clinical trial under the supervision of the U.S. Food and Drug Administration (FDA). Being the company’s first clinical trial, it will help change the manner in which solid cancerous tumors are treated. Additionally, it will also help prove that the company has what is referred to as the “Holy Grail” for diabetes. This is an encapsulation technology, which can stay inside one’s body and help protect the cells from the body’s own immune response.

Cell-in-a-Box®, the company’s signature live-cell encapsulation technology is one of the most reliable cell encapsulation technology currently available on the market. Its clinical trial for treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC, which has been planned to happen in the near future, is expected to attract a lot of attention from organizations, companies as well investors.


About Author

Leave A Reply